Arbutus Biopharma
ABUS
99 hedge funds and large institutions have $149M invested in Arbutus Biopharma in 2021 Q3 according to their latest regulatory filings, with 23 funds opening new positions, 31 increasing their positions, 23 reducing their positions, and 14 closing their positions.
75% more call options, than puts
Call options by funds: $13.5M | Put options by funds: $7.71M
70% more capital invested
Capital invested by funds: $87.5M → $149M (+$61.2M)
64% more first-time investments, than exits
New positions opened: 23 | Existing positions closed: 14
35% more repeat investments, than reductions
Existing positions increased: 31 | Existing positions reduced: 23
9% more funds holding
Funds holding: 91 → 99 (+8)
5.19% more ownership
Funds ownership: 29.99% → 35.18% (+5.2%)
Top Buyers
| 1 |
Millennium Management
New York
|
+$3.4M |
| 2 |
N
Nuveen
Charlotte,
North Carolina
|
+$2.98M |
| 3 |
Barclays
London,
United Kingdom
|
+$2.08M |
| 4 |
SG Americas Securities
New York
|
+$2M |
| 5 |
State Street
Boston,
Massachusetts
|
+$1.67M |
Top Sellers
| 1 |
RI
RTW Investments
New York
|
-$4.15M |
| 2 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$1.1M |
| 3 |
CAC
Cowen and Company
New York
|
-$720K |
| 4 |
Two Sigma Advisers
New York
|
-$363K |
| 5 |
Acadian Asset Management
Boston,
Massachusetts
|
-$361K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
CS
101
Credit Suisse
Zurich,
Switzerland
| – | -$262K | -86,771 | Closed |
|
102
UBS Group
Zurich,
Switzerland
| – | -$189K | -62,310 | Closed |
|
103
AQR Capital Management
Greenwich,
Connecticut
| – | -$58K | -19,036 | Closed |
|
104
Assenagon Asset Management
Senningerberg,
Luxembourg
| – | -$54K | -17,851 | Closed |
|
105
Qube Research & Technologies (QRT)
London,
United Kingdom
| – | -$47K | -15,474 | Closed |
|
|
IWM
106
IHT Wealth Management
Chicago,
Illinois
| – | -$45K | -15,000 | Closed |
|
|
BCA
107
Bay Colony Advisors
Concord,
Massachusetts
| – | -$39K | -13,000 | Closed |
|
|
SIG
108
Sargent Investment Group
Bethesda,
Maryland
| – | -$37K | -12,339 | Closed |
|
|
SC
109
Scotia Capital
Toronto,
Ontario, Canada
| – | -$35K | -11,690 | Closed |
|
|
RG
110
Retirement Group
San Diego,
California
| – | -$2K | -500 | Closed |
|
|
AF
111
Advisornet Financial
Minnetonka,
Minnesota
| – | -$1K | -272 | Closed |
|
ABUS Hedge Fund Activity: Q3 2021 in Review
99 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Arbutus Biopharma (ABUS) for Q3 2021, worth a combined $149M — up 70% from $87.5M a quarter earlier.
Buyers outnumbered sellers: 23 funds opened new ABUS positions and 14 closed out — a net gain of 9 holders — while 31 added to existing stakes and 23 trimmed.
The largest buyer was Millennium Management, opening a new position worth an estimated $3.4M. The largest seller was RTW Investments, cutting an estimated $4.15M.
- 99 institutional investors held Arbutus Biopharma (ABUS) as of Q3 2021, up from 91 in Q2 2021.
- Funds reported $149M of Arbutus Biopharma stock for Q3 2021, up 70% quarter-over-quarter.
- 23 funds opened new Arbutus Biopharma positions in Q3 2021 and 14 closed out, a net change of +9 holders.
- The largest Arbutus Biopharma buyer in Q3 2021 was Millennium Management, an estimated $3.4M added.
- The largest Arbutus Biopharma seller in Q3 2021 was RTW Investments, an estimated $4.15M sold.
Based on aggregated 13F filings for Q3 2021.